Farastuk Bozorgmehr: Why the Negative Results of the TREASURE Trial Matter for ES-SCLC
Farastuk Bozorgmehr, Head of Clinical Trials Unit Thoracic Oncology at Thoraxklinik Heidelberg, shared a post on LinkedIn: “Today is a special day for me: our TREASURE trial has been published in […]
Read the full articleYou might also wanna read
Sellas: James Molloy hebt Ziel auf 25 Dollar
Sellas Life Sciences steht vor den wichtigsten Wochen der Firmengeschichte. Genau zwei klinische Ereignisse fehlen noch für den finalen Date
GSK’s licensor Hansoh Pharma announces positive phase III results for Ris-Rez in China patient population
ARTEMIS-008 met its primary endpoint of overall survival in advanced or relapsed small-cell lung cancer
Lung Cancer Patients on Drug From China’s Akeso Lived Longer
Promising news announced #ASCO26 for patients with #lungcancer. Dr. Roy Herbst comments on ivonescimab, noting the initial study results fro
Dose-reduced thoracic radiotherapy shows promise for older and frail stage III NSCLC patients in randomized trial
In a randomized open-label trial, Wei-Xiang Qi and colleagues investigate the feasibility of dose-reduced thoracic radiotherapy to mitigate
plos.io·1mo agoA Phase Ib Study of Tislelizumab Plus SYS6010 in Immunotherapy-Pretreated Locally Advanced or Metastatic NSCLC
Conditions : NSCLC Interventions : Drug: SYS6010 Sponsors : Sichuan University Not yet recruiting
Tumore im Mundraum: Einfacher Abstrich erkennt Krebs in nur einer Stunde
Die Diagnose von Mundkrebs ist bisher oft unangenehm und invasiv. Eine neue Methode könnte künftig Abhilfe schaffen: Ein molekularer Bürsten
Comments
Sign in to join the conversation.
No comments yet. Be the first.